Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
HIV Infections
Interventions
DRUG

GSK3640254 Oral tablet

GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.

DRUG

[14C]-GSK3640254 intravenous infusion

\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.

DRUG

[14C]-GSK3640254 powder

\[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY